IP Library › Granted Patent US 12,491,239
Granted Patent B2
US 12,491,239 · App. 17/821,730 · Granted Dec 9, 2025

Patent

Inventors: Clifford Shone (Salisbury, GB); April Roberts (Salisbury, GB); Helen Ahern (Salisbury, GB); Michael Maynard-Smith (Salisbury, GB); John Landon (Newcastle Emlyn, GB)
Assignees: Secretary of State for Health and Social Care; MicroPharm Limited
A61K39/08A61K38/164A61K39/40C07K14/33C07K16/1282A61K2039/505C07K2317/76C07K2319/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,491,239
App. No.
17/821,730
Granted
Dec 9, 2025
Kind
B2
Abstract

The present application relates to recombinant Clostridium difficile antigens based on a fusion protein that consists of or comprises a first amino acid sequence and a second amino acid sequence, wherein: a) the first amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of residues 1500-1850 of a C. difficile Toxin A sequence or residues 1500-1851 of a C. difficile Toxin B sequence; and b) the second amino acid sequence is provided by an amino acid sequence that has at least 80% sequence identity with an amino acid sequence consisting of a long repeat unit located within amino acid residues 1851-2710 of a C. difficile Toxin A sequence or within amino acid residues 1852-2366 of a C. difficile Toxin B sequence; though with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2710 of a C. difficile Toxin A and with the proviso that the fusion protein is not a polypeptide comprising amino acid residues 543-2366 of a C. difficile Toxin B. Also provided is the use of said antigens for the prevention/treatment/suppression of Clostridium difficile infection (CDI), together with methods for generating said antigens, methods for generating antibodies that bind to said antigens, and the use of said antibodies for the prevention/treatment/suppression of CDI.

Claims (6)

1 . A method for preventing or suppressing C. difficile infection in a human, said method comprising administering to said human a therapeutically effective amount of a nucleic acid; wherein the nucleic acid encodes a protein, the protein comprising:

a) an amino acid sequence that comprises amino acid residues 767-2366 of a C. difficile Toxin B sequence; or

b) an amino acid sequence that comprises amino acid residues 1145-2366 of a C. difficile Toxin B sequence;

with the proviso that the protein is not a polypeptide comprising an amino acid sequence having at least 97% sequence identity to amino acid residues 544-767 of the C. difficile Toxin B sequence of SEQ ID NO:2 or SEQ ID NO:4;

wherein the protein can elicit a toxin-neutralizing immune response; and

wherein said C. difficile Toxin B sequences are the C. difficile Toxin B amino acid residue sequence 767-2366 or 1145-2366 of SEQ ID NO:2 or the C. difficile Toxin B amino acid residue sequence 767-2366 or 1145-2366 of SEQ ID NO:4.

Priority Claims (1)
GB 1016742 · Oct 5, 2010 · national
Continuity (4)
Continuation 17224404 · Apr 7, 2021
Division 16511503 · Jul 15, 2019
Division 13878150
Related Publication 20230165949A1 · Jun 1, 2023
References Cited (33)
US 5919463A · Thomas, Jr. et al. · 1999 [cited by applicant]
US 8481692B2 · Sidhu · 2013 [cited by examiner]
US 9745354B2 · Ruppen · 2017 [cited by examiner]
US 20050287150A1 · Ambrosino et al. · 2005 [cited by applicant]
US 20070065466A1 · Windle et al. · 2007 [cited by applicant]
WO 9612802A1 · 1996 [cited by applicant]
WO 9859053A1 · 1998 [cited by applicant]
WO 0061762A1 · 2000 [cited by applicant]
WO 2007146139A2 · 2007 [cited by applicant]
WO 2010017383A1 · 2010 [cited by applicant]
WO 2011067616A1 · 2011 [cited by applicant]
WO 2012046061A3 · 2012 [cited by applicant]
Alpar et al. (Expert Opinion Drug Delivery vol. 2 No. 5, pp. 829-842). [cited by examiner]
Belyi, I.F., and N.A. Varfolomeeva, “Construction of a Fusion Protein Carrying Antigenic Determinants of Enteric Clostridial Toxins,” FEMS Microbiology Letters 225(2):325-329, Aug. 2003. [cited by applicant]
Boslego, J.W., and C.D. Deal, “Gonorrhea Vaccines: Etiologic Agent and Pathogenesis,” Vaccines and Immunotherapy, Chapter 17, 1 page, 1991. [cited by applicant]
Castagliuolo, I., et al., “Clostridium difficile Toxin A Carboxyl-Terminus Peptide Lacking ADP-Ribosyltransferase Activity Acts as a Mucosal Adjuvant,” Infections and Immunity 72(5):2827-2836, May 2004. [cited by applicant]
Colman, P.M., “Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions,” Research in Immunology 145(1):33-36, 1994. [cited by applicant]
Ellis, R.W., “New Technologies for Making Vaccines,” in Stanley J. Cryz, Jr. (ed.), Vaccines, W.B. Saunders Company, Philadelphia, 1988, Chapter 29, pp. 568-574. [cited by applicant]
Greenspan, N.S., and E.Di Cera, “Defining Epitopes: It's Not as Easy as It Seems,” Nature Biotechnology 17(10):936-937, Oct. 1999. [cited by applicant]
Harlow, E., and D. Lane, “Antibodies a Laboratory Manual,” Cold Spring Harbor Press Inc., Cold Spring Harbor, New York, 1988, pp. 23-35. [cited by applicant]
Ho, J.G.S., et al., “Crystal Structure of Receptor-Binding C-Terminal Repeats From Clostridium difficile Toxin A,” Proceedings of the National Academy of Sciences of the USA (PNAS) 102(51):18373-18378, Dec. 2005. [cited by applicant]
Houghten, R.A., et al., “Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antibody Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift,” in Cold Spring… [cited by applicant]
Pruitt, R.N., et al., “Structural Determinants of Clostridium difficile Toxin A Glucosyltransferase Activity,” Journal of Biological Chemistry 287(11):8013-8020, Mar. 2012. [cited by applicant]
Pruitt, R.N., et al., “Structural Organization of the Functional Domains of Clostridium difficile Toxins A and B,” Proceedings of the National Academy of Sciences of the USA (PNAS) 107(30):13467-13472, Jul. 2010. [cited by applicant]
Reinert, D.J., et al., “Structural Basis for the Function of Clostridium difficile Toxin B,” Journal of Molecular Biology 351(5):973-981, Sep. 2005. [cited by applicant]
Skolnick, J., and J.S. Fetrow, “From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era,” Trends in Biotechnology 18(1):34-39, Jan. 2000. [cited by applicant]
Von Eichel-Streiber, C., et al., “Comparative Sequence Analysis of the Clostridium difficile Toxins A and B,” Molecular and General Genetics 233(1-2):260-268, May 1992. [cited by applicant]
United Kingdom Intellectual Property Office, Patents Act 1977: Search Report Under Section 17, mailed Feb. 4, 2011, issued in corresponding Great Britain Application No. GB 101672.7, filed Oct. 5, 2010, 5 pages. [cited by applicant]
European Patent Office Written Opinion mailed Feb. 15, 2013, issued in corresponding International Patent Application No. PCT/GB2011/051910, 7 pages. [cited by applicant]
Written Opinion of the International Searching Authority mailed Apr. 5, 2013, issued in corresponding International Patent Application No. PCT/GB2011/051910, 6 pages. [cited by applicant]
Response to the Written Opinion of the International Searching Authority issued in corresponding International Patent Application No. PCT/GB2011/051910, mailed Apr. 15, 2013, 9 pages. [cited by applicant]
International Preliminary Report on Patentabilily mailed May 14, 2013, issued in corresponding International Patent Application No. PCT/GB2011/051910, 8 pages. [cited by applicant]
Redwan, EL.-R.M., et al., “Production and Purification of Ovine Anti-Tetanus Antibody,” Comparative Immunology, Microbiology and Infectious Diseases 28(3):167-176, May 2005. [cited by applicant]